SecBot SecBot
PRESS-RELEASE ·Filed Mar 5, 2026

EVAX

Evaxion
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight ▲ Bullish

Traders should monitor upcoming clinical data readouts for EVX-01 (3-year results) and EVX-04 (IND filing) in H2 2026, as well as potential new partnership announcements leveraging the strengthened balance sheet and validated AI platform. The expanded ATM program creates optionality but also potential dilution risk if utilized.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.40
T+0 close · Mar 5, 2026 · via day close
Latest settled
+14.71%
T+60 · $3.90
Vs SPY
+3.41%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $3.40entry
  2. T+1 · 9mo ago −5.29%α −3.98% · $3.22
  3. T+5 · 8mo ago +22.94%α +25.18% · $4.18
  4. T+20 · 8mo ago +11.18%α +14.97% · $3.78
  5. T+60 · 6mo ago +14.71%α +3.41% · $3.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion reported strong 2025 financial and clinical progress, highlighted by a $7.5M upfront from MSD for its AI-discovered vaccine EVX-B3, improved cash position of $23.2M extending runway into 2027, and compelling phase 2 data for its cancer vaccine EVX-01 showing 75% objective response rate in advanced melanoma. The company also expanded its pipeline and secured enhanced funding capacity via an amended ATM program allowing up to $45.5M in future share issuances.

Key Financial Metrics

Revenue
$7.5M
+124.7% YoY
EPS
$-0.02
Deal Value
$599.5M

Key Facts

  • Received $7.5M from MSD for the option exercise on infectious disease candidate EVX-B3, with potential for up to $592M in milestone payments
  • Cash and cash equivalents increased to $23.2M (from $6.0M in 2024), funding operations into H2 2027
  • EVX-01 showed 75% objective response rate and 92% durable clinical benefit at two years in phase 2 melanoma trial
  • Net loss narrowed to $7.7M in 2025 from $10.6M in 2024, driven by higher revenue and lower R&D and G&A expenses
  • Amended ATM facility allows potential issuance of up to $45.5M in shares through March 2028
  • Added two new pipeline candidates: EVX-04 (AML) and EVX-B4 (Group A Streptococcus), and launched AI-Immunology™ expansion into autoimmune diseases

Financial Impact

$7.5M in revenue from MSD deal, $30M+ total capital inflow in 2025, $14M expected cash burn in 2026

revenuecashnet lossequitydilution

Risk Factors

  • High reliance on future milestone payments from MSD, which are uncertain and non-guaranteed
  • Potential dilution from ATM share issuances if market conditions prompt capital raises
  • Clinical development risk in ongoing and future trials, particularly for novel AI-discovered targets

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3250320

Track record

50 reports on EVAX

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +21.62% at T+1 after the Oct 19, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026